Research Topics
Genomes and GenesSpecies | Jaffer AjaniSummaryAffiliation: The University of Texas Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancerJ A Ajani
Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Houston, TX 77030, USA
Ann Oncol 23:2638-42. 2012..We hypothesized that a model based on clinical parameters could predict pathCR with a high (≥60%) probability...
Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from theNational Cancer Data BaseKaye M Reid-Lombardo
Department of Surgery, Mayo Clinic, 200 First Street S W, Rochester, MN 55905, USA
J Gastrointest Surg 11:410-9; discussion 419-20. 2007..9%) (p<0.01). These data support previous publications demonstrating that patients with diseases requiring specialized treatment have lower operative mortality when treated at high-volume centers...
Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancerXiaoxiang Guan
Department of Epidemiology, The University of Texas M, d, Anderson Cancer Center, Houston, Texas 77030, USA
J Exp Clin Cancer Res 28:94. 2009..Given that these genes are involved in tumor growth and progression including angiogenesis, dissemination, and invasiveness, we hypothesized that these polymorphisms would be associated with survival in patients with gastric cancer...
AGUIA: autonomous graphical user interface assembly for clinical trials semantic data servicesMiria C Correa
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
BMC Med Inform Decis Mak 10:65. 2010..AGUIA uses a semantic web formalism, resource description framework (RDF), and a bottom-up design of knowledge bases that employ the S3DB tool as the starting point for the client's interface assembly...
The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancerXiaoxiang Guan
Department of Epidemiology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
BMC Gastroenterol 9:77. 2009..In this study, we investigated the association between potentially functional SNPs of these two genes and risk of gastric cancer in a US population...
Can we understand the clinical biology of gastric cancer and exploit it? May be, but it is a challenge!Jaffer A Ajani
Ann Surg Oncol 14:3290-2. 2007
Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcomeJ A Ajani
Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
J Clin Oncol 23:1237-44. 2005....
US intergroup anal carcinoma trial: tumor diameter predicts for colostomyJaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Mail Stop 426, Houston, TX 77030 4009, USA
J Clin Oncol 27:1116-21. 2009..Established prognostic variables for patients with anal carcinoma include tumor diameter, clinical nodal status, and sex, but pretreatment variables that would predict the likelihood of colostomy are unknown...
Future developments in esophageal cancer researchJaffer A Ajani
Department of GI Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Gastroenterol Clin North Am 38:183-8, x. 2009..The progress that has been made against esophageal carcinoma is limited. Many relevant issues remain. Herein the author discusses his outlook for the treatment of this disease, which has a steadily rising incidence...
Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiationJaffer A Ajani
Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA
Dig Dis Sci 55:1098-105. 2010..Upon further expansion and validation, these results may provide a biomarker-based understanding of heterogeneous clinical biology of patients with anal carcinoma...
Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinomaJ A Ajani
Department of Gastrointestinal Medical Oncology, Stop 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 22:2774-80. 2004..A multi-institutional study of preoperative chemoradiotherapy was done to assess the R0 resection rate, pathologic complete response (pathCR) rate, safety, and survival in patients with resectable gastric carcinoma...
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancerJaffer A Ajani
M D Anderson Cancer Center, The University of Texas, 1515 Holcombe Boulevard, Box 426, Houston, TX, 77030, USA
Invest New Drugs 23:479-84. 2005....
Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic responseJaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
J Clin Oncol 24:3953-8. 2006..We hypothesized that, in a cooperative group setting, preoperative chemoradiotherapy would induce a 20% pathologic complete response (pathCR) rate. Combined-modality therapy quality, survival, and safety were secondary end points...
Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimenJaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 113:945-55. 2008....
Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinomaJaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 23:6957-65. 2005..S-1 with cisplatin is considered highly active in Japanese gastric cancer patients. Therefore, we initiated a phase I pharmacokinetic study of this combination in our gastric cancer patients...
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinomaJaffer A Ajani
Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Box 426, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 23:5660-7. 2005..We compared the overall response rate (ORR) and safety of docetaxel plus cisplatin (DC) with DC plus fluorouracil (DCF) to select either DC or DCF as the experimental treatment in the ensuing phase III part of trial V-325...
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trialJaffer A Ajani
Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Mail Stop 426, Houston, Texas 77030, USA
JAMA 299:1914-21. 2008..Chemoradiation as definitive therapy is the preferred primary therapy for patients with anal canal carcinoma; however, the 5-year disease-free survival rate from concurrent fluorouracil/mitomycin and radiation is only approximately 65%...
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study GroupJaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 25:3210-6. 2007..Using validated instruments, we prospectively assessed QOL (even after completion of protocol treatment) as one of the secondary end points of the V325 phase III trial...
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study GroupJaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 25:3205-9. 2007..However, a prospective evaluation of clinical benefit in AGGEC patients has never before been reported in a phase III setting...
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113Jaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 26:4551-6. 2008..The primary end point was to assess whether any approach would achieve a >or= 77.5% 1-year survival rate, surpassing the historical 66% rate from the Radiation Therapy Oncology Group (RTOG) protocol 9405...
Molecular mechanisms in cancer: what should clinicians know?Jaffer Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Semin Oncol 32:2-4. 2005..In this way, clinicians might recommend combinations of molecularly targeted agents and other therapies on the basis of an individual patient's proteomic profile...
Evolving chemotherapy for advanced gastric cancerJaffer A Ajani
University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, Texas 77030, USA
Oncologist 10:49-58. 2005..Recently reported phase III results with these agents now demonstrate positive developments in the treatment options for patients with advanced gastric cancer...
Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancerJaffer A Ajani
Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Oncology (Williston Park) 17:20-2. 2003..Our preliminary data suggest that the proportion of patients with significant pathologic response can be increased by using the three-step strategy...
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junctionJaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
Cancer 100:2347-54. 2004..Patients with localized esophageal carcinoma often develop locoregional and distant disease recurrence. The current study investigated the outcome of a new chemotherapy combination as induction therapy before chemoradiotherapy...
Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinomaJ A Ajani
Department of Gastrointestinal Oncology and Digestive Diseases, U T M D Anderson Cancer Center, Houston, TX 77030, USA
Invest New Drugs 16:175-7. 1998..We studied a 120-hour infusion schedule of Taxol in patients with metastatic measurable colorectal carcinoma who had had one prior 5-FU-based chemotherapy...
Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinomaJulie G Izzo
Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
Mol Cancer Ther 5:2844-50. 2006..We hypothesized that activated NF-kappaB would define clinical biology irrespective of the type of chemotherapy or sequence administered...
Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxelJaffer A Ajani
Department of GI Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 426, Houston, TX 77030, USA
Expert Opin Pharmacother 7:1627-31. 2006..Future developments will lead to the incorporation of docetaxel in regimens with improved safety profile...
Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinomaJaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030, USA
Oncology (Williston Park) 16:16-8. 2002..Modifications in doses and schedule are warranted to increase the tolerability of the regimen. Phase III trials are necessary to establish the clinical utility of irinotecan/cisplatin in these patient populations...
Docetaxel for gastric and esophageal carcinomasJaffer A Ajani
Department of Gastrointestinal Oncology, The University of Texas, M D Anderson Cancer Center, Houston 77030 4009, USA
Oncology (Williston Park) 16:89-96. 2002....
[Is neoadjuvant therapy for locally advanced stomach carcinoma standard?]J A Ajani
Department of GI Oncology, Box 426, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
Chirurg 73:312-5. 2002....
CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II studyJaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 94:641-6. 2002..This Phase II study assessed the response rate and toxicity profile of the combination CPT-11 and cisplatin administered weekly to patients with untreated, advanced adenocarcinoma of the stomach or the gastroesophageal junction...
A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junctionJ A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 92:279-86. 2001..After chemoradiotherapy, patients underwent surgery. The feasibility of this approach, curative resection rates, patient survival, and patterns of failure were assessed...
Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinomaJ A Ajani
Department of GI Oncology, Box 78, University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4095, USA
Oncology (Williston Park) 15:52-4. 2001..The combination of irinotecan and cisplatin is active against gastric or gastroesophageal adenocarcinoma and should undergo further study. The addition of other active drugs or radiation therapy to this regimen would be of interest...
Recent developments in oral chemotherapy options for gastric carcinomaJ A Ajani
Department of Gastrointestinal Medical Oncology and Digestive Diseases, University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
Drugs 58:85-90. 1999..In conclusion, future clinical research is likely to focus on the development of convenient outpatient regimens with efficacy equal to that of intravenous regimens...
Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinomaJ A Ajani
Departments of Gastrointestinal Medical Oncology and Digestive Diseases and Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4095, USA
J Clin Oncol 17:2403-11. 1999....
Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancersJaffer Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
Cancer 107:221-31. 2006....
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxaneJ A Ajani
The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Mail Stop 426, Houston, Texas, 77030, USA
Invest New Drugs 24:441-6. 2006..With the primary endpoint of assessing ixabepilone's response rate against metastatic gastric cancer previously treated with a taxane, we performed a multi-center phase II trial...
Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11)Jaffer A Ajani
The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 116:4007-13. 2010..A prognostic factor analysis for anal cancer from a prospective database has been published from only 1 study (N = 110). To confirm and uncover new prognostic factors, we analyzed the prospective database of intergroup RTOG 98-11...
An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 studyJaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 106:1908-16. 2006..Immunogen G17DT elicits a specific and high-affinity AGA. The authors evaluated G17DT vaccination given with cisplatin plus 5-fluorouracil for the treatment gastric adenocarcinoma...
Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. IntroductionJaffer A Ajani
Department of Gastrointestinal Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Oncology (Williston Park) 17:10-2. 2003
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trialJaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, TX 77030, USA
J Clin Oncol 28:1547-53. 2010..Patients with advanced gastric or gastroesophageal adenocarcinoma need more efficacious and safer treatments than established today. S-1, a contemporary oral fluoropyrimidine, can provide that advantage...
Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinomaJaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 24:663-7. 2006..We conducted a phase II multi-institutional trial, in the West, in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma to evaluate activity and safety of this combination...
Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junctionJaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer 116:1656-63. 2010..It was hypothesized that chemoradiotherapy with fluoropyrimidine, taxane, and camptothecin would have preserved or improved efficacy with no compromise in safety...
Docetaxel-related side effects and their managementJackie Baker
University of Texas MD Anderson Cancer Center, Gastrointestinal Medical Oncology, Faculty Center, Houston, TX 77030, USA
Eur J Oncol Nurs 13:49-59. 2009..It is, therefore, important to share and build on experiences, through research and discussion, to maximise the healthcare professional's ability to offer the best standard of care to patients...
Induction and concurrent taxanes enhance both the pulmonary metabolic radiation response and the radiation pneumonitis response in patients with esophagus cancerMatthew McCurdy
Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 76:816-23. 2010..The primary aim of this study was to assess pulmonary radiation toxicity quantitatively in patients who received thoracic radiotherapy combined with induction and/or concurrent chemotherapy with or without taxanes for esophageal cancer...
Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagusPooja R Rohatgi
Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 104:1349-55. 2005..Future investigations should focus on reducing the proportion of residual carcinoma and metastatic disease progression in patients with esophageal carcinoma...
Endoscopic ultrasound after preoperative chemoradiation can help identify patients who benefit maximally after surgical esophageal resectionBanke Agarwal
Department of GI Medicine and Nutrition, Medical Oncology and Thoracic and Cardiovascular Surgery, MD Anderson Cancer Center, Houston, Texas, USA
Am J Gastroenterol 99:1258-66. 2004..EUS and EUS-guided FNA can be helpful in identifying residual tumor in the lymph nodes after preoperative chemoXRT to select patients who benefit maximally from surgery...
Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation responseJennifer Sims-Mourtada
Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 12:6565-72. 2006..CONCLUSIONS: These results suggest that activation of the Hh pathway may promote tumor repopulation after chemoradiotherapy and contribute to chemoradiation resistance in esophageal cancers...
Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancerJames C Yao
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Clin Cancer Res 10:4109-17. 2004..Given the importance of Sp1 in the expression of VEGF, our data suggest that dysregulated Sp1 expression and activation play important roles in VEGF overexpression and, thus, gastric cancer development and progression...
Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junctionKazumasa Fujitani
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 444, P.O. Box 301402, Houston, TX 77230-1402, USA
Ann Surg Oncol 14:1305-11. 2007....
Treatment issues in pediatric gastric adenocarcinomaMatthew T Harting
Department of Pediatric Surgical Oncology, M.D. Anderson Cancer Center, Houston, TX, USA
J Pediatr Surg 39:e8-10. 2004..The authors report a case of an 8-year-old girl with gastric adenocarcinoma. The case will be followed by a brief discussion of the presentation, current management guidelines, and prognosis of this rare pediatric entity...
Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagusHeta Javeri
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 113:1302-8. 2008..Whether the type of therapy influences the outcomes remains largely unanswered. It is hypothesized that induction chemotherapy (IC) or the type of cytotoxics used would not influence patient outcomes...
Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancerMichael J Overman
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 426, Houston, TX 77030, USA
Cancer 116:1446-53. 2010..The objective of the current study was to evaluate the efficacy and tolerability of a weekly formulation of DCF...
Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinomaJulie G Izzo
Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030-4009, USA
J Clin Oncol 24:748-54. 2006..Additional understanding of NF-kappaB regulated pathways may uncover potential therapeutic targets...
A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancerYixing Jiang
Department of Gastrointestinal Medical Oncology, The University of Texas, MD, Anderson Cancer Center, Houston, Texas 77030, USA
Clin Exp Metastasis 21:755-64. 2004..Therefore, dysregulated expression of IGF-IR and/or Sp1 may contribute to the growth and metastasis of gastric cancer and potentially can be a target of therapeutic intervention...
Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancerShu-Lian Wang
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
World J Gastroenterol 12:5501-8. 2006..However, local and distant recurrence and toxicity remain to be a problem. Innovative approaches are needed to improve the outcome...
Rapid development of S-1 in the west for therapy of advanced gastric carcinomaJaffer A Ajani
Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
Gan To Kagaku Ryoho 33:117-20. 2006..Phase I/II studies of the combination of S-1 plus cisplatin have been completed and a global phase III study, accruing rapidly, is comparing S-1 plus cisplatin to 5-fluorouracil plus cisplatin (a reference regimen)...
Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal refluxBanke Agarwal
Department of Gastrointestinal Medicine and Nutrition, M D Anderson Cancer Center, Houston, Texas, USA
Ann Thorac Surg 79:1716-23. 2005..In this study, we investigated potential differences in clinical outcomes in esophageal adenocarcinoma patients based on the presence of identifiable Barrett's mucosa and/or history of symptomatic GERD...
Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcomeKim L Wang
Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer 109:658-67. 2007..It is not known whether EGFR plays a similar role in esophageal and EGJ adenocarcinomas...
The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiationYan Gu
Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 106:1017-25. 2006..The authors suggest modification of the tumor-lymph node-metastasis (TNM) staging classification (ypTNM) to include the number of positive LNs in the ypN1 category...
Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinomaDavid Hong
Department of GI Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 104:1620-6. 2005..Baseline NPA (> 1), reflecting the regional nodal metastases, is an independent predictor of OS. Baseline PET may become a useful stratification factor in randomized trials and for individualizing therapy...
Loss of Krüppel-like factor 4 expression contributes to Sp1 overexpression and human gastric cancer development and progressionMasashi Kanai
Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 12:6395-402. 2006..CONCLUSIONS: Our data suggests that disruption of KLF4-mediated negative regulation contributes to the molecular events of Sp1 overexpression and to the development and progression of human gastric cancer...
Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic indexArthur Hung
Department of Radiation Oncology, The University of Texas, M. D. Anderson Cancer Center, Houston 77030, USA
Cancer 97:1195-202. 2003..These rates are comparable to the best results reported with mitomycin-C and 5-FU. Without the normally severe toxicity, cisplatin-based therapy results in a wider therapeutic index...
Gastric cancer: advances in adjuvant and adjunct therapyKatsuhiko Higuchi
Department of Gastrointestinal Oncology, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Boulevard, Box 426, Houston, TX 77030, USA
Curr Treat Options Oncol 4:413-9. 2003..In our opinion, all of the patients in the West who have had a curatively resected node-positive gastric carcinoma (R0 resection) should be offered an option of receiving postoperative chemoradiotherapy...
Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiationLucian R Chirieac
Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 103:1347-55. 2005..The findings in the current study supported the concept of downstaging by preoperative therapy...
The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinomaSantosh B Murthy
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Oncology 78:316-22. 2010..We hypothesized that the standardized uptake value (SUV) of positron emission tomography (PET) after chemoradiation would define the clinical outcome in patients...
Effects of sex and racial/ethnic group on the pattern of gastric cancer localizationJames C Yao
Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Gastric Cancer 5:208-12. 2002..Proximal gastric cancer represents a distinct subtype of gastric cancer that may have different biology, risk factors, and clinical behavior...
Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junctionKazumasa Fujitani
Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Ann Surg Oncol 14:2010-7. 2007....
Treatment outcomes of resected esophageal cancerWayne Hofstetter
Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
Ann Surg 236:376-84; discussion 384-5. 2002..The increased use of preoperative chemoradiation, better preoperative staging, and other time-dependent factors may have contributed to the observed increase in survival...
Medical treatment for advanced gastroesophageal adenocarcinomaPutao Cen
Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Curr Opin Gastroenterol 23:631-5. 2007..Advanced gastroesophageal cancer is an incurable condition and more research is desirable. Considerable new and important information, however, has become available...
A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinomaJaffer A Ajani
Department of GI Medical Oncology, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Invest New Drugs 24:353-7. 2006..Further development of this combination is warranted once an effective method to ameliorate or prevent myalgias can be established...
Clinical benefit of palliative radiation therapy in advanced gastric cancerMichelle M Kim
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Acta Oncol 47:421-7. 2008..Local progression of advanced gastric cancer often manifests as bleeding, dysphagia/obstruction, or pain. We evaluated the magnitude and durability of palliation with radiotherapy (RT)...
Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiationHeta Javeri
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 115:624-30. 2009..The authors evaluated initial standardized unit value (iSUV) of 18F-fluoro-2-deoxy-D-glucose positron emission tomography and its association with overall survival and the degree of pathologic response after surgery...
Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancersMadan G Luthra
Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77054, USA
Clin Cancer Res 13:912-9. 2007..In the current study, we did an in-depth investigation of the expression of 1q21-1q25 region genes to uncover the role of the EDC and its flanking genes in CTXRT response...
Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagusPooja R Rohatgi
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
Int J Gastrointest Cancer 36:69-76. 2005..Frequent presence of malignant nodes in the resected specimens of ACA patients resulted in a shorter time-to-metastases suggesting that ACA patients need better systemic control...
Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysisNirav Thosani
Department of Gastroenterology, Hepatology and Nutrition, The University of Texas Medical School, Houston, Texas 77030, USA
Gastrointest Endosc 75:242-53. 2012..EC limited to the mucosa (T1a) can be treated effectively with minimally invasive endoscopic therapy, whereas submucosal (T1b) EC carries relatively high risk of lymph node metastasis and requires surgical resection...
Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial marginsJohn A Harvin
Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
J Thorac Cardiovasc Surg 143:412-20. 2012..We aimed to determine the frequency and significance of a close (<1 mm) or involved CRM in patients undergoing esophagectomy after CRT...
Docetaxel-related side effects and their managementJackie Baker
University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Eur J Oncol Nurs 12:253-68. 2008..It is therefore important to share and build on experiences, through research and discussion, to maximise the healthcare professional's ability to offer the best standard of care to patients...
Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancerLiwei Wang
Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 9:6371-80. 2003..Given the importance of Sp1 in the expression of multiple molecules key to tumor cell survival, growth, and angiogenesis, its disregulated expression and activation may play important roles in gastric cancer development and progression...
Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinomaChia Jui Yen
Department of Molecular and Cellular Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer Res 68:2632-40. 2008..In addition, Bay 11-7082 and rapamycin may potentially be chemopreventive drugs against Barrett's esophagus-associated EAC...
Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imagingJeremy J Erasmus
Department of Diagnostic Imaging, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Thorac Oncol 1:478-86. 2006..We evaluated the use of integrated computed tomography (CT)-PET among patients with esophageal cancer being considered for resection after CRT...
Longterm survival of a Western patient with metastatic gastric cancer treated with S-1 plus cisplatinEric D Tetzlaff
Department of Gastrointestinal Medical Oncology, Box 426, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Gastric Cancer 9:140-3. 2006..This patient exemplifies the strategy of maintenance therapy with S-1 alone and shows a prolonged and excellent response to S-1 and cisplatin...
Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinomaLucian R Chirieac
Department of Pathology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Clin Cancer Res 11:2229-36. 2005..04). CONCLUSIONS: Our study showed that patients with esophageal or EGJ adenocarcinoma who have signet-ring cell or mucinous histology benefited substantially from preoperative chemoradiation and esophagectomy...
Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcomeTsung Teh Wu
Department of Pathology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Am J Surg Pathol 31:58-64. 2007..The extent of residual carcinoma is a reliable and reproducible predictor of survival; this grading system may allow a novel and early means of comparing outcomes after different neoadjuvant treatment regimens...
Significance of the depth of tumor invasion and lymph node metastasis in superficially invasive (T1) esophageal adenocarcinomaLixia Liu
Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Am J Surg Pathol 29:1079-85. 2005....
Preoperative and adjuvant therapies for upper gastrointestinal cancersGauri Varadhachary
MD Anderson Cancer Center, GI Medical Oncology Department, University of Texas, 1515 Holcombe Boulevard, Mailbox 426, Houston, TX 77030, USA
Expert Rev Anticancer Ther 5:719-25. 2005..The role of molecular profiling is evolving and will help us differentiate the responders from the nonresponders...
Prognostic significance of differentially expressed miRNAs in esophageal cancerYuxin Hu
Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX77030, USA
Int J Cancer 128:132-43. 2011..Our data indicate that further evaluation of miR-30e and miR-16-2 as prognostic biomarkers is warranted in patients with esophageal adenocarcinoma. In addition, the role of miR-34a in esophageal cancer also warrants further study...
Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgeryMichelle M Kim
Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 71:167-72. 2008....
Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinomaPutao Cen
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer 112:1020-7. 2008..The authors hypothesized that LVI status would subclassify T1b cancers and facilitate new therapeutic strategies...
Incidence, natural history, and patterns of locoregional recurrence in gastric cancer patients treated with preoperative chemoradiotherapyValerie K Reed
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 71:741-7. 2008..To retrospectively determine the incidence and patterns (in-field, marginal, or out-of-field) of locoregional gastric cancer recurrence in patients who received preoperative chemoradiotherapy and to determine the outcome in these patients...
The crosstalk of mTOR/S6K1 and Hedgehog pathwaysYan Wang
Department of Molecular and Cellular Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
Cancer Cell 21:374-87. 2012..Together, our results established a crosstalk between the mTOR/S6K1 and HH pathways, which provides a mechanism for SMO-independent Gli1 activation and also a rationale for combination therapy for EAC...
Radiation pneumonitis: local dose versus [18F]-fluorodeoxyglucose uptake response in irradiated lungThomas Guerrero
Division of Radiation Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Int J Radiat Oncol Biol Phys 68:1030-5. 2007..To quantify the relationship between the local radiation dose received and the posttreatment positron emission tomography/computed tomography (PET/CT) [(18)F]2-fluoro-2-deoxyglucose (FDG) uptake in the lung...
Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patientsBouthaina S Dabaja
Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 101:518-26. 2004..Because cancer-directed surgery is associated with high morbidity and mortality in primary centers, these patients should be referred to a tertiary center for adequate treatment...
Value of endoscopic ultrasound staging in conjunction with the evaluation of lymphovascular invasion in identifying low-risk esophageal carcinomaPutao Cen
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 112:503-10. 2008..It was hypothesized that endoscopic ultrasonography (EUS) in concert with detailed histopathologic evaluation would identify low-risk cancers for an appropriate but organ-preserving strategy...
Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancerWeida Gong
Department of Neurosurgery, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Clin Cancer Res 11:1386-93. 2005..CONCLUSION: Dysregulated Stat3 activation may play an important role in VEGF overexpression and elevated angiogenic phenotype in gastric cancer and contribute to gastric cancer development and progression...
Endoscopic ultrasonography-identified celiac adenopathy remains a poor prognostic factor despite preoperative chemoradiotherapy in esophageal adenocarcinomaS Chris Malaisrie
Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Tex 77030, USA
J Thorac Cardiovasc Surg 131:65-72. 2006..These patients should be stratified in future multimodality trials. The investigation of induction chemotherapy before concurrent chemoradiotherapy might be warranted in this high-risk group of patients...
Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumorsPaulo M Hoff
Department of Gastrointestinal Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
Clin Cancer Res 9:134-42. 2003..CONCLUSIONS: The recommended S-1 dose for future studies is 30 mg/m(2) twice daily, and diarrhea is the most frequent toxic effect. Additional trials of S-1 in the treatment of patients with solid tumors are warranted...
Association of age and survival in patients with gastroesophageal cancer undergoing surgery with or without preoperative therapyFadi Braiteh
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer 115:4450-8. 2009..For this study, the authors explored their institution's large surgical experience to examine the impact of age on long-term patient survival and surgical complications...
Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinomaMahmoud Goodarzi
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Mod Pathol 22:1612-21. 2009..In addition, phosphorylated histone H3 is a potential supportive marker to histology in differentiating low-grade dysplasia from indefinite for dysplasia and high-grade dysplasia from adenocarcinoma in the mucosal biopsy samples...
MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinomaHushan Yang
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 15:5744-52. 2009..Although microRNA (miRNA) expression signatures have been associated with the etiology and prognosis of several types of cancers, their roles in the development of esophageal adenocarcinoma have not been extensively evaluated...
The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinomaS Chris Malaisrie
Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 107:967-74. 2006..Overall survival and disease-free survival were increased in patients who received CCRT, especially in the subset of patients who had more advanced disease...
Research Grants
- Prediction of Pathologic Complete Response by Gene Expression Profiling in EsophaJaffer A Ajani; Fiscal Year: 2010..Our goal is to pave the way for a strategy in the future that will allow administration of effective therapy, improve safety, and preserve the esophagus in some patients. ..
